Pharmafile Logo
Pharmafocus logo
Advanced Search

lenvatinib

Showing 5 posts of 5 posts found.

eisa0002

Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …

News
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016
Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …

News
Eisai logo

FDA grants Eisai’s Lenvima priority review for kidney cancer

January 19, 2016
Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma

The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …

News
Eisai

Eisai submits new cancer combo to EMA for approval

January 12, 2016
Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …

News
fda

FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill

February 16, 2015
Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid

The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review.  Lenvima …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024